Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, USA.
J Hosp Infect. 2010 Nov;76(3):206-10. doi: 10.1016/j.jhin.2010.06.023. Epub 2010 Sep 16.
Implementation of meticillin-resistant Staphylococcus aureus (MRSA) decolonisation programmes has been increasing and the emergence of mupirocin resistance has been reported. However, the patient-level risk factors associated with mupirocin resistance are not clear. In this study, independent predictors of mupirocin resistance in MRSA among Providence Veterans Affairs Medical Center patients with MRSA-positive culture dates between 1 July 2004 and 30 June 2008 were identified using a frequency-matched case-control study. Forty cases (mupirocin-resistant) were matched on culture date quarter and year to 270 controls (mupirocin-susceptible). The adjusted conditional logistic regression model identified three significant independent predictors associated with mupirocin resistance in MRSA: (1) exposure to mupirocin in the year prior to the culture date [odds ratio (OR): 9.84; 95% confidence interval (CI): 2.93-33.09]; (2) Pseudomonas aeruginosa infection in the year before the culture-related admission (4.85; 1.20-19.61); and (3) cefepime use in the year prior to culture (2.80; 1.03-7.58). In sensitivity analyses, previous mupirocin exposure was associated with low-level [minimum inhibitory concentration (MIC) 8-128mg/L; 23 cases, 202 controls; OR: 6.32; 95% CI: 1.58-25.33] and high-level (MIC ≥256mg/L; 17 cases, 151 controls; OR: 11.18; 95% CI: 1.89-66.30) mupirocin resistance. To our knowledge, this is the first case-control study to reveal a strong association between previous mupirocin exposure and subsequent mupirocin resistance in MRSA, with demonstrated robustness in low- and high-level mupirocin resistance. Mupirocin susceptibility monitoring is critical for facilities instituting decolonisation with mupirocin as increased use may reduce effectiveness through resistance.
耐甲氧西林金黄色葡萄球菌(MRSA)去定植方案的实施一直在增加,并且已经报道了莫匹罗星耐药的出现。然而,与莫匹罗星耐药相关的患者水平的危险因素尚不清楚。在这项研究中,采用频数匹配病例对照研究,确定了 2004 年 7 月 1 日至 2008 年 6 月 30 日期间普罗维登斯退伍军人事务医疗中心 MRSA 阳性培养日期的 MRSA 患者中莫匹罗星耐药的独立预测因子。40 例(莫匹罗星耐药)按培养季度和年份与 270 例对照(莫匹罗星敏感)相匹配。调整后的条件逻辑回归模型确定了三个与 MRSA 中莫匹罗星耐药相关的显著独立预测因子:(1)在培养日期前一年接触莫匹罗星[比值比(OR):9.84;95%置信区间(CI):2.93-33.09];(2)在与培养相关的入院前一年发生铜绿假单胞菌感染(4.85;1.20-19.61);(3)在培养前一年使用头孢吡肟(2.80;1.03-7.58)。在敏感性分析中,先前的莫匹罗星暴露与低水平[最低抑菌浓度(MIC)8-128mg/L;23 例,202 例对照;OR:6.32;95%CI:1.58-25.33]和高水平(MIC≥256mg/L;17 例,151 例对照;OR:11.18;95%CI:1.89-66.30)莫匹罗星耐药有关。据我们所知,这是第一项病例对照研究,揭示了 MRSA 中先前莫匹罗星暴露与随后莫匹罗星耐药之间的强烈关联,并在低水平和高水平莫匹罗星耐药方面具有稳健性。对于使用莫匹罗星进行去定植的机构,莫匹罗星敏感性监测至关重要,因为使用增加可能会通过耐药降低效果。